. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985.
2. Perri MG, Limacher MC, Castel‐Roberts K, Daniels MJ, Durning PE, Janicke DM, et al. Comparative effectiveness of three doses of weight‐loss counseling: Two‐year findings from the rural LITE trial. Obesity. 2014;22(11):2293-300.
3. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-6.
4. Unick JL, Hogan PE, Neiberg RH, Cheskin LJ, Dutton GR, Evans‐Hudnall G, et al. Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention. Obesity. 2014;22(7):1608-16.
5. Christian JG, Tsai AG, Bessesen DH. Interpreting weight losses from lifestyle modification trials: using categorical data. Int J Obes. 2010;34(1):207-9.
6. Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, Jeffery R, et al. Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity. 2015;23(7):1353-6.
7. Waring ME, Schneider KL, Appelhans BM, Busch AM, Whited MC, Rodrigues S, et al. Early-treatment weight loss predicts 6-month weight loss in women with obesity and depression: implications for stepped care. J Psychosom Res. 2014;76(5):394-9.
8. Miller CK, Nagaraja HN, Weinhold KR. Early weight-loss success identifies nonresponders after a lifestyle intervention in a worksite diabetes prevention trial. Journal of the Academy of Nutrition and Dietetics. 2015;115(9):1464-71.
9. Unick J, Leahey T, Kent K, Wing R. Examination of whether early weight loss predicts 1-year weight loss among those enrolled in an Internet-based weight loss program. Int J Obes. 2015;39(10):1558-60.
10. Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Heymsfield SB, Nguyen AM. Predictors of attrition and weight loss success: Results from a randomized controlled trial. Behav Res Ther. 2009;47(8):685-91.
11. Nackers LM, Ross KM, Perri MG. The Association Between Rate of Initial Weight Loss and Long-Term Success in Obesity Treatment: Does Slow and Steady Win the Race? Int J Behav Med. 2010;17(3):161-7.
12. Wadden TA, Letizia KA. Predictors of attrition and weight loss in patients treated by moderate and severe caloric restriction. In: Wadden TA, VanItallie TB, editors. Treatment of the seriously obese patient . New York, NY: Guilford Press; 1992. p. 383-410.
13. Tronieri JS, Wadden TA, Chao AM, Pearl RL, Alamuddin N, Berkowitz RI. Early weight loss in behavioral treatment predicts later rate of weight loss and response to pharmacotherapy. Ann Behav Med. 2018;XX:1-6.
14. French SA, Epstein LH, Jeffery RW, Blundell JE, Wardle J. Eating behavior dimensions. Associations with energy intake and body weight. A review. Appetite. 2012;59(2):541-9.
15. Yanovski SZ, Yanovski JA. Toward Precision Approaches for the Prevention and Treatment of Obesity. JAMA. 2018;319(3):223-4.
16. Drapeau V, King N, Hetherington M, Doucet E, Blundell J, Tremblay A. Appetite sensations and satiety quotient: Predictors of energy intake and weight loss. Appetite. 2007;48(2):159-66.
17. Drapeau V, Blundell J, Gallant AR, Arguin H, Després J-, Lamarche B, et al. Behavioural and metabolic characterisation of the low satiety phenotype. Appetite. 2013;70:67-72.
18. Thomas EA, Mcnair B, Bechtell JL, Ferland A, Cornier M, Eckel RH. Greater hunger and less restraint predict weight loss success with phentermine treatment: Hunger Predicts Response to Phentermine. Obesity. 2016;24(1):37-43.
19. Batra P, Das SK, Salinardi T, Robinson L, Saltzman E, Scott T, et al. Eating behaviors as predictors of weight loss in a 6 month weight loss intervention. Obesity. 2013;21(11):2256-63.
20. Murdaugh DL, Cox JE, Cook EW, Weller RE. FMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program. Neuroimage. 2012;59(3):2709-21.
21. Brockmeyer T, Sinno M, Skunde M, Wu M, Woehning A, Rudofsky G, et al. Inhibitory Control and Hedonic Response towards Food Interactively Predict Success in a Weight Loss Programme for Adults with Obesity. OBESITY FACTS. 2016;9(5):299-309.
22. Leahey T, Xu X, Unick J, Wing R. A preliminary investigation of the role of self-control in behavioral weight loss treatment. Obes Res & Clin Prac. 2014;8(2):E149-53.
23. Barlow P, Reeves A, McKee M, Galea G, Stuckler D. Unhealthy diets, obesity and time discounting: a systematic literature review and network analysis: Time discounting, diets and obesity. Obesity Reviews. 2016;17(9):810-9.
24. Amlung M, Petker T, Jackson J, Balodis I, MacKillop J. Steep discounting of delayed monetary and food rewards in obesity: a meta-analysis. Psychol Med. 2016;46(11):2423-34.
25. Galioto R, Bond D, Gunstad J, Pera V, Rathier L, Tremont G. Executive functions predict weight loss in a medically supervised weight loss programme: Executive functions and weight loss. Obesity Science & Practice. 2016.
26. Weygandt M, Mai K, Dommes E, Ritter K, Leupelt V, Spranger J, et al. Impulse control in the dorsolateral prefrontal cortex counteracts post-diet weight regain in obesity. Neuroimage. 2015;109:318-27.
27. Dalton M, Hollingworth S, Blundell J, Finlayson G. Weak Satiety Responsiveness Is a Reliable Trait Associated with Hedonic Risk Factors for Overeating among Women. Nutrients. 2015;7(9):7421-36.
28. Epstein LH, Salvy SJ, Carr KA, Dearing KK, Bickel WK. Food reinforcement, delay discounting and obesity. Physiol Behav. 2010;100(5):438-45.
29. Epstein LH, Temple JL, Neaderhiser BJ, Salis RJ, Erbe RW, Leddy JJ. Food reinforcement, the dopamine D₂ receptor genotype, and energy intake in obese and nonobese humans: Erratum. Behav Neurosci. 2008;122(1):250-.
30. Saelens BE, Epstein LH. Reinforcing Value of Food in Obese and Non-obese Women. Appetite. 1996;27(1):41-50.
31. Temple JL, Legierski CM, Giacomelli AM, Salvy S, Epstein LH. Overweight children find food more reinforcing and consume more energy than do nonoverweight children. Am J Clin Nutr. 2008;87(5):1121-7.
32. Appelhans BM, Woolf K, Pagoto SL, Schneider KL, Whited MC, Liebman R. Inhibiting food reward: Delay discounting, food reward sensitivity, and palatable food intake in overweight and obese women. Obesity. 2011;19(11):2175-82.
33. Carr KA, Lin H, Fletcher KD, Epstein LH. Food reinforcement, dietary disinhibition and weight gain in nonobese adults. Obesity. 2014;22(1):254-9.
34. Rollins BY, Dearing KK, Epstein LH. Delay discounting moderates the effect of food reinforcement on energy intake among non-obese women. Appetite. 2010;55(3):420-5.
35. Rothemund Y, Preuschhof C, Bohner G, Bauknecht H, Klingebiel R, Flor H, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007;37(2):410-21.
36. Finlayson G, King N, Blundell JE. Liking vs. wanting food: Importance for human appetite control and weight regulation. Neurosci Biobehav Rev. 2007;31(7):987-1002.
37. Blundell J, Finlayson G, Gibbons C, Caudwell P, Hopkins M. The biology of appetite control: Do resting metabolic rate and fat-free mass drive energy intake? Physiol Behav. 2015;152(Pt B):473-8.
38. Williams D. Neural integration of satiation and food reward: Role of GLP-1 and orexin pathways. Physiol Behav. 2014;136:194-9.
39. Williams RL, Wood LG, Collins CE, Morgan PJ, Callister R. Energy homeostasis and appetite regulating hormones as predictors of weight loss in men and women. Appetite. 2016;101:1-7.
40. Harrold JA, Dovey TM, Blundell JE, Halford JCG. CNS regulation of appetite. Neuropharmacology. 2012;63(1):3-17.
41. Näslund E, Grybäck P, Backman L, Jacobsson H, Holst JJ, Theodorsson E, et al. Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci. 1998;43(5):945-52.
42. Horner KM, Byrne NM, Cleghorn GJ, Näslund E, King NA. The effects of weight loss strategies on gastric emptying and appetite control. Obesity Reviews. 2011;12(11):935-51.
43. Vazquez Roque MI, Camilleri M, Stephens DA, Jensen MD, Burton DD, Baxter KL, et al. Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People. Gastroenterology. 2006;131(6):1717-24.
44. Strohacker K, McCaffery J, MacLean P, Wing R. Adaptations of leptin, ghrelin or insulin during weight loss as predictors of weight regain: A review of current literature. Int J Obes. 2014;38(3):388-96.
45. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - Effect of obesity and weight reduction. Int J Obes. 2001;25(8):1206-14.
46. Erez G, Tirosh A, Rudich A, Meiner V, Schwarzfuchs D, Sharon N, et al. Phenotypic and genetic variation in leptin as determinants of weight regain. Int J Obes. 2011;35(6):785-92.
47. Shih L, Liou T, Chao JC-, Kau H, Wu Y, Shieh M, et al. Leptin, Superoxide Dismutase, and Weight Loss: Initial Leptin Predicts Weight Loss. Obesity. 2006;14(12):2184-92.
48. Ramel A, Arnarson A, Parra D, Kiely M, Bandarra NM, Martinéz JA, et al. Gender difference in the prediction of weight loss by leptin among overweight adults. Ann Nutr Metab. 2010;56(3):190-7.
49. Labayen I, Ortega FB, Ruiz JR, Lasa A, Simón E, Margareto J. Role of Baseline Leptin and Ghrelin Levels on Body Weight and Fat Mass Changes after an Energy-Restricted Diet Intervention in Obese Women: Effects on Energy Metabolism. J Clin Endocrinol Metab. 2011;96(6):E996-E1000.
50. Stubbs J, Whybrow S, Teixeira P, Blundell J, Lawton C, Westenhoefer J, et al. Problems in identifying predictors and correlates of weight loss and maintenance: implications for weight control therapies based on behaviour change. Obesity Reviews. 2011;12(9):688-708.
51. Gettens KM, Gorin AA. Executive function in weight loss and weight loss maintenance: a conceptual review and novel neuropsychological model of weight control. J Behav Med. 2017:1-15.
52. Colombo O, Ferretti V, Ferraris C, Trentani C, Vinai P, Villani S, et al. Is drop-out from obesity treatment a predictable and preventable event? Nutr J. 2014;13(1):13-.
53. Handjieva-Darlenska T, Holst C, Grau K, Blaak E, Martinez JA, Oppert J, et al. Clinical Correlates of Weight Loss and Attrition During a 10-Week Dietary Intervention Study: Results from the NUGENOB Project. Obesity Facts. 2012;5(6):928-36.
54. Carels RA, Wott CB, Young KM, Gumble A, Darby LA, Oehlhof MW, et al. Successful weight loss with self-help: A stepped-care approach. J Behav Med. 2009;32(6):503-9.
55. Unick J, Dorfman L, Leahey T, Wing R. A preliminary investigation into whether early intervention can improve weight loss among those initially non-responsive to an internet-based behavioral program. J Behav Med. 2016;39(2):254-61.
56. Jakicic JM, Tate DF, Lang W, Davis KK, Polzien K, Rickman AD, et al. Effect of a Stepped-Care Intervention Approach on Weight Loss in Adults: A Randomized Clinical Trial. JAMA. 2012;307(24):2617-26.
57. Pi-Sunyer FX, Becker DM, Bouchard C, Carleton RA, Colditz GA, Dietz WH, et al. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr. 1998;68(4):899-917.
58. Wadden T, Hollander P, Klein S, Niswender K, Woo V, Hale P, et al. Weight maintenance and additional weight loss with phentermine after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443-51.
59. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N Engl J Med. 2005;353(20):2111-20.
60. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145(2):81-90.
61. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935-43.
62. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean MEJ, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, phentermine. Int J Obes. 2012; 2011; 2013;36(6):843-54.
63. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9774):1341-52.
64. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity. 2012;20(2):330-42.
65. Moldovan CP, Weldon AJ, Daher NS, Schneider LE, Bellinger DL, Berk LS, et al. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings: Effects of Phentermine on Weight Loss. Obesity. 2016;24(11):2344-50.
66. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am J Clin Nutr. 1999;69(6):1108-16.
67. Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: A 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30(1):27-32.
68. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Phentermine in Weight Management. N Engl J Med. 2015;373(1):11-22.
69. Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, Desai J, et al. Safety and effectiveness of longer‐term phentermine use: clinical outcomes from an electronic health record cohort. Obesity. 2019;27(4):591-602.
70. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long‐term phentermine pharmacotherapy for obesity. Obesity. 2011;19(12):2351-60.
71. Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes. 2014;38(2):292.
72. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. British medical journal. 1968;1(5588):352.
73. Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Current therapeutic research, clinical and experimental. 1972;14(11):726-38.
74. Langlois KJ, Forbes JA, Bell GW, Grant JG. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Current therapeutic research, clinical and experimental. 1974;16(4):289-96.
75. Brightwell DR, Naylor CS. Effects of a combined behavioral and pharmacological program on weight loss. International journal of obesity. 1979;3(2):141-8.
76. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse‐controlled release for obesity. Diabetes, Obesity and Metabolism. 2010;12(10):876-82.
77. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults. Obesity. 2013;21(11):2163-71.
78. Acosta A, Camilleri M, Shin A, Vazquez-Roque M, Iturrino J, Burton D, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015;148(3):537-.
79. Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, et al. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity. 2010;18(12):2301-10.
80. Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365(21):1969-79.
81. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403.
82. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289(14):1805-12.
83. Tronieri JS, Wadden TA, Walsh OA, Berkowitz RI, Alamuddin N, Gruber K, et al. Effects of Liraglutide Plus Phentermine in Adults with Obesity Following 1 Year of Treatment by Liraglutide Alone: A Randomized Placebo-Controlled Pilot Trial. Metabolism. 2019. Epub ahead of print.
84. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II (BDI-II) Manual. San Antonio, TX: Harcourt Brace; 1996.
85. Wadden TA, Foster GD. Weight and Lifestyle Inventory (WALI). Obesity. 2006;14(3S):99S-118S.
86. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77.
87. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol. 1973;47(2):415-21.
88. Willems M, Quartero AO, Numans ME. How Useful Is Paracetamol Absorption as a Marker of Gastric Emptying? A Systematic Literature Study. Dig Dis Sci. 2001;46(10):2256-62.
89. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog phentermine on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784-93.
90. Stunkard AJ, Messick S. Eating Inventory Manual. New York: Psychological Corporation; 1988.
91. Lowe MR, Butryn ML, Didie ER, Annunziato RA, Thomas JG, Crerand CE, et al. The Power of Food Scale. A new measure of the psychological influence of the food environment. Appetite. 2009;53(1):114-8.
92. Carver CS, White TL. Behavioral Inhibition, Behavioral Activation, and Affective Responses to Impending Reward and Punishment: The BIS/BAS Scales. J Pers Soc Psychol. 1994;67(2):319-33.
93. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768-74.
94. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242-51.
95. Yanovski SZ, Marcus MD, Wadden TA, Walsh BT. The Questionnaire on Eating and Weight Patterns-5: An updated screening instrument for binge eating disorder: QEWP-5. Int J Eat Disord. 2015;48(3):259-61.
96. Meule A, Hermann T, Kübler A. A short version of the Food Cravings Questionnaire—Trait: the FCQ-T-reduced. Frontiers in Psychology. 2014 Mar 4;5:190.
97. van Strien T, Van Strien T, Frijters JER, Frijters JER, Bergers GPA, Bergers GPA, et al. The Dutch eating behavior questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. Int J Eat Disord. 1986;5(2):295-315.
98. Welsh EM, Jeffery RW, Levy RL, Langer SL, Flood AP, Jaeb MA, et al. Measuring perceived barriers to healthful eating in obese, treatment-seeking adults. J Nutr Educ Behav. 2012;44(6):507-12.
99. Clark MM, Abrams DB, Niaura RS, Eaton CA, Rossi JS. Self-efficacy in weight management. J Consult Clin Psychol. 1991;59(5):739.
100. Kroll T, Kehn M, Ho P, Groah S. The SCI exercise self-efficacy scale (ESES): development and psychometric properties. Int J Behav Nutr Phys Act. 2007;4(1):34.
101. Ball K, Crawford D. An investigation of psychological, social and environmental correlates of obesity and weight gain in young women. Int J Obes. 2006;30(8):1240.
102. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606-13.
103. Cohen S, Kamarck T, Mermelstein R. A Global Measure of Perceived Stress. J Health Soc Behav. 1983;24(4):385-96.
104. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992:473-83.
105. Paffenbarger RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1995;142(9):889-903.
106. Polsky S, Ogden LG, MacLean PS, Giles ED, Brill C, Wyatt HR. Biomarker Profile Does Not Predict Weight Loss Success in Successful and Unsuccessful Diet-Reduced Obese Individuals: A Prospective Study. ISRN Obesity. 2013;2013:1-5.
107. Hwang D, Schmitt WA, Stephanopoulos G, Stephanopoulos G. Determination of minimum sample size and discriminatory expression patterns in microarray data. Bioinformatics. 2002;18(9):1184-93.
108. Shao L, Fan X, Cheng N, Wu L, Cheng Y. Determination of minimum training sample size for microarray-based cancer outcome prediction-an empirical assessment. PloS one. 2013;8(7):e68579.
109. Moldovan CP, Weldon AJ, Daher NS, Schneider LE, Bellinger DL, Berk LS, Hermé AC, Aréchiga AL, Davis WL, Peters WR. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity. 2016 Nov;24(11):2344-50.
110. Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, et al. Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety study. Obesity. 2017 May;25(5):857-65.
111. Diggle PJ, Heagerty P, Liang K, Zeger SL. Analysis of Longitudinal Data. 2nd ed. Oxford: Oxford University Press; 2013.
112. Tronieri JS, Wadden TA, Berkowitz RI, Chao AM, Pearl RL, Alamuddin N, et al. A randomized trial of lorcaserin and lifestyle counseling for maintaining weight loss achieved with a low-calorie diet. Obesity. 2018;26(2):299-309.
113. Fabricatore AN, Wadden TA, Higginbotham AJ, Faulconbridge LF, Nguyen AM, Heymsfield SB, et al. Intentional weight loss and changes in symptoms of depression: A systematic review and meta-analysis. Int J Obes. 2011;35(11):1363-76.
114. Carr KA, Epstein LH. Influence of sedentary, social, and physical alternatives on food reinforcement. Health Psychology. 2018 Feb;37(2):125.
115. Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite. 2009;52(2):430-6.
116. Schulte, E. M., Smeal, J. K., Lewis, J., & Gearhardt, A. N. (2018). Development of the highly processed food withdrawal scale. Appetite, 131, 148-154.
117. Cardaciotto, L., Herbert, J.D., Forman, E.M., Moitra, E., Farrow, V. (2008). The assessment of present-moment awareness and acceptance: The Philadelphia Mindfulness Scale. Assessment, 15(2), 204-223.
118. Taheri, Shahrad, et al. "Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index." PLoS medicine 1.3 (2004): e62.